Staging and Treatment of Dementia



Similar documents
Update on Treatment of the Dementias

2012 Medical School for Actuaries Nov. 6-7, 2012 Session #1: Alzheimer s Disease

Primary Care Update January 28 & 29, 2016 Alzheimer s Disease and Mild Cognitive Impairment

Objectives. Aging and Forgetfulness Define Dementia Types of Dementia Treatment

Dementia: Delivering the Diagnosis

The Pharmacist s Role in Recognition and Management of Alzheimer s

Long Term Care Formulary HCD Anti-Dementia Drugs (e.g. donepezil, galantamine, rivastigmine, memantine)

Costs of Medical Care for Dementia Patients in Taiwan: A Population-Based Study

EMR Decision Support Tools for Alzheimer s and Related Dementias

Disclosures. Case: Ms. K. Case: Ms. K. Dementia: Considering When to Start, Stop, and Continue Medications 4/23/15. * Nothing to disclose

Dementia: A How-To Approach for Clinicians NOVEMBER 12, 2015 MARIAN HODGES, MD, MPH REGIONAL MEDICAL DIRECTOR, GERIATRICS, PROVIDENCE - OREGON

Donepezil, galantamine, rivastigmine (review) and memantine for the treatment of Alzheimer s disease (amended)

Cholinesterase inhibitors and memantine use for Alzheimer s disease TOPIC REVIEW

TABLE OF CONTENTS. 1. Introduction Dementia and Alzheimer Prevalence. 2. Global Alzheimer Market and Performance. 2.1.

Montreal Cognitive Assessment (MoCA) Debbie Froese, B.M.R.-O.T., B.A. Christine Knight, Ph.D.,R.Psych.

BEST in MH clinical question-answering service

Donepezil, galantamine, rivastigmine and memantine for Alzheimer s disease

Alzheimer Disease (AD)

DEMENTIA AND MILD COGNITIVE IMPAIRMENT John P. Moriarty, MD Week 7

Dementa Formulary Guidance [v1.0]

EMR DECISION SUPPORT TOOLS FOR ALZHEIMER S AND RELATED DEMENTIAS

Alzheimer's: The Latest Assessment and Treatment Strategies

MCDB 4777/5777 Molecular Neurobiology Lecture 38 Alzheimer s Disease

Shared Care Protocol for the Prescription of Memantine for Alzheimer s disease

Guidelines for Dementia Syndrome

Donepezil hydrochloride (Aricept) Drug treatment for Alzheimer s disease

Objectives. Evaluation of Memory Loss. Cognitive Impairment. Clinical Questions. Medicare Wellness Visit

Update of Pharmacological Intervention Recommendations for the Canadian Consensus Conference on the Diagnosis and Treatment of Dementia 2012

Pharmacotherapy of BPSD. Pharmacological interventions. Anti-dementia drugs. Abhilash K. Desai MD Medical Director Alzheimer s Center of Excellence

Everyone has mild memory lapses from time to time. You go

DRUG APPROVAL PROCESS FOR THE TREATMENT OF ALZHEIMER S DISEASE

Emergency Room Treatment of Psychosis

NHS ONEL and NELFT Shared Care Guidelines. Management of medications for Alzheimer s disease. Patient Name : Date of Birth: NHS No:

Month/Year of Review: January 2012 Date of Last Review: October 2006

Memantine (Ebixa) Drug treatment for Alzheimer s disease

Local Clinical Trials

Being an advocate for good care. Useful medications What to expect When to be concerned

Diagnosis and Initial Management of Cognitive Disorders

Primary Endpoints in Alzheimer s Dementia

Sunday March 16 NEUROCOGNITIVE DISORDERS, THE DSM-5, AND INFORMED TREATMENT CHOICES

Normal Aging versus Alzheimer Disease Drugs to treat the symptoms that are not due to old age. Leah Wright, HBSc. BSP student June 2006

Down Syndrome and Alzheimer s Disease. Overview. Alzheimer s Disease vs. Dementia 1/31/2012

Galantamine hydrobromide (Reminyl) Drug treatment for Alzheimer s disease

basics of alzheimer s disease What it is and what you can do

Changing the Trajectory of Alzheimer s Disease: How a Treatment by 2025 Saves Lives and Dollars

Shared Care Guideline-Use of Donepezil, Galantamine, Rivastigmine and Memantine in Dementia

Community Network for Dementia and Critical Path in Japan

Dementias have become a major public health concern. Clinical Guidelines

U.S. Scientific Update Aricept 23 mg Tablets. Dr. Lynn Kramer President NeuroScience Product Creation Unit Eisai Inc.

Cognitive Testing for Underwriting Life Insurance

keyword: donepezil The pharmacological management of Alzheimer s disease: The place of donepezil 28 BPJ Issue 30

Alzheimer s and Depression: What is the Connection?

Prediction of the MoCA and the MMSE in Out-patients with the risks of cognitive impairment

Medication for Dementia (Acetylcholinesterase Inhibitors)

Alzheimer s disease. What is Alzheimer s disease?

Donepezil (Aricept ), Galantamine (Reminyl XL ), Rivastigmine (Exelon ) and Memantine (Ebixa )

Alzheimer s Disease Alzheimer s Disease. Markets, Pipeline and Opportunities. April By John Bates Ph.D. 1 Copyright 2009 Biopharm Reports

Mild cognitive impairment (MCI) and dementia in Parkinson Disease (PDD) Iracema Leroi Senior Lecturer/Honorary Consultant Older Adult Psychiatry

Technology appraisal guidance Published: 23 March 2011 nice.org.uk/guidance/ta217

Mixed Dementia 9/21/2015. No financial relationships. Case History 76yo M semi-retired CPA c/o forgetfulness

Geriatric Assessment Tools. Dr. Hermes

Is There a Need for New Symptomatic Therapies for Alzheimer s Disease & What Have We Learned from Past Trials of Symptomatic Therapies?

Alzheimer s Drugs. Oregon Health Resources Commission. Subcommittee Report. Update #1 October 2006

The Independent In-Person Assessment Process

THE CLINICIAN SHOULD UTILIZE THIS GUIDANCE AND INTERPRET IT IN THE CLINICAL CONTEXT OF THE INDIVIDUAL PATIENT.

ASSESSMENT OF THE OLDER ADULT

**Form 1: - Consultant Copy** Telephone Number: Fax Number: Author: Dr Bernard Udeze Pharmacist: Claire Ault Date of issue July 2011

A 5-HT 6 antagonist in advanced development for the treatment of mild and moderate Alzheimer s disease: idalopirdine (Lu AE58054)

Acetylcholinesterase Inhibitors and Memantine Clinical Indication: Treatment of Dementia in Alzheimer s Disease (AD)

An Evidence-based Critical Appraisal of a Topic: Effectiveness of High Dose Donepezil for Advanced Alzheimer s Disease

Memantine (Namenda ) [Developed, April 2010; Revised, March 2012; March 2014] MEDICAID DRUG USE REVIEW CRITERIA FOR OUTPATIENT USE

Montreal Cognitive Assessment (MoCA) as Screening tool for cognitive impairment in mtbi.

Dementia. Your medicine. Information for you. Follow us on Find us on Facebook at

N-methyl-D-aspartate (NMDA) Receptor Antagonist Memantine (CWM TAF ONLY)

P/OTD 541 Critical Analysis of Occupational Therapy Practice OTD 601 Capstone CRITICALLY APPRAISED TOPIC (CAT) WORKSHEET

Dementia Causes and Neuropsychological Evaluation of the Older Adult

Submission to the Review of Pharmaceutical Benefits Scheme Anti-Dementia Drugs to treat Alzheimer s disease.

Cognitive impairment (CI) in Multiple Sclerosis

FINANCIAL CAPACITY IN THE ELDERLY. Linda Ganzini, MD, MPH Neisha D Souza, MD

IJBCP International Journal of Basic & Clinical Pharmacology

How To Write Long Term Care Insurance

Prescribing Framework for Donepezil in the Treatment and Management of Dementia

As people age, changes to the structure

Rehabilitation Integrated Transition Tracking System (RITTS)

Management of Alzheimer s Disease Partner s Pharmacy Education National Series

Chemobrain. Halle C.F. Moore, MD The Cleveland Clinic October 3, 2015

Table 1: Approved Memantine Adult Dosage Recommendations 1-6

Age Associated Cognitive Decline and Mild Cognitive Impairment (MCI)

UPDATES TO NEUROCOGNITIVE DISORDERS IN DSM-5 and DSM-5 DESK REFERENCE UPDATED

Clinical Audit: Prescribing antipsychotic medication for people with dementia

Participating in Alzheimer s Disease Clinical Trials and Studies

Dementia Friendly Health Care Setting

Assessment of Cognition in Depression Treatment Studies. Philip D. Harvey, PhD University of Miami Miller School of Medicine

Dementia in Hospice Care Part I: Stages, Hospice Guidelines, and Assessing Pain/Discomfort

Common causes of dementia

Review Article Efficacy of Memantine, Donepezil, or Their Association in Moderate-Severe Alzheimer s Disease: A Review of Clinical Trials

Steps to getting a diagnosis: Finding out if it s Alzheimer s Disease.

The Senior Care Continuum: A quick guide to the options

Access to Alzheimer s disease drug treatments and memory services. By Yvonne Kay and Simon Kitchen

Technology Report. Issue 58 September Cholinesterase Inhibitors for Alzheimer s Disease: A Systematic Review of Randomized Controlled Trials

Transcription:

Staging and Treatment of Dementia Ami Hall DO 10/25/14 1

Objectives What are the two most common types of dementias seen in a primary care office How are they staged What treatments are available Definition of Neurocognitive Disorder Evidence of significant cognitive decline from a previous level of performance in one or more cognitive domains such as complex attention, executive function, learning, memory, language, perceptual motor or social cognition. 2

Alzheimer s Disease Alzheimer s disease is an irreversible, progressive brain disease that slowly destroys memory and thinking skills and, eventually even the ability to carry out the simplest tasks of daily living. (NIA) Vascular Dementia Vascular dementia is a general term describing problems with reasoning, planning, judgment, memory and other thought processes caused by brain damage from impaired blood flow to your brain. (Mayo Clinic) 3

Age is the biggest risk factor Alz.org Alz.org 4

Not all dementia is Alzheimer s disease Jags, 1999 Case Presentation 85 y/o male Recently widowed Family visiting from out of town Spoiled food, unpaid bills, and expired medication PMH: HTN and Hyperlipidemia 5

Memory Test Options MMSE MOCA Mini Cog Clock drawing test Mini Cog Say three words and have the patient repeat them Clock drawing test (1 point if correct) Repeat 3 words (1 point for each recalled word) Scoring 0 2 with abnormal CDT = dementia Scoring of 1 2 with normal CDT is negative for dementia Score of 3 is negative for dementia 6

Clock Drawing Test Bathing Dressing Toileting Transfer Continence Feeding Katz Basic ADLs 7

Lawton Brody Instrumental ADLs Ability to use the telephone Shopping Food preparation Laundry Mode of transportation Responsibility for own medications Management of finances and bills Lab work and Imaging CBC, CMP, TSH, vitamin B12, (RPR) CT brain without contrast MRI (without contrast) if gait abnormality and/or tremor is present or if vascular cause is a concern 8

Case Presentation Bloodwork negative Imaging nondiagnostic MMSE: 18 Clock: 2 Dependent in all IADLs Able to do all his ADLs 9

CDR Staging CDR dementia 0 No dementia 0.5 MCI 1.0 Mild 2.0 Moderate 3.0 Severe Subjective No +/ +/ memory loss Measurable No + ++ +++ ++++ memory loss IADLS No No Yes Yes Yes BADLs No No No Yes Yes Driving Safely Yes >50% <50% No No Medications No No ChEI ChEI and NMDA ant ChEI and NMDA ant Pharmaceutical Treatment Acetylcholinesterase Inhibitors Aricept (donepezil) Exelon (rivastigmine) Razadyne (galatamine) NMDA antagonist Namenda (memantine) 10

FDA Approved Therapies Mild Moderate Severe Donepezil 5-10 mg 5-10 mg 10 mg Donepezil (Aricept 23) 23 mg/d Galantamine Rivastigmine* 16-24 mg/d 6(3*)-12 mg/d 4.6/9.5/13.3 patch Memantine 10-20 mg/d *FDA approved for mild-moderate Parkinson s Disease related dementia 11

NMDA antagonist More effective when used with ACEI May help with agitation Memantine and Donepezil Combination Therapy Mean Change from Baseline Worsening Improvement 4.0 3.0 2.0 1.0 0-1.0-2.0-3.0 Severe Impairment Battery Placebo Memantine -4.0 Baseline 4 8 12 18 24 End Point No. of Patients Study Week (LOCF) Memantine 196 197 190 185 181 171 196 Placebo 197 194 180 169 164 153 196 LS Mean Difference -1.2-1.5-3.1-2.7-3.4-3.4 P value.06.03 <0.001 0.006 <0.001 <0.001 Mean Change from Baseline Worsening Improvement Alzheimer Disease Cooperative Study - Activities of Daily Living Inventory -1.0 0-1.0-2.0-3.0-4.0 Baseline 4 8 12 18 24 End Point No. of Patients Study Week (LOCF) Memantine 198 198 190 185 181 172 198 Placebo 197 195 182 170 163 152 197 LS Mean Difference -0.8-1.1-1.3-1.4-1.6-1.4 P value.03.01.02.03.02.03 Tariot P, et al. JAMA. 2004;3: 317-324. 12

Nonpharmaceutical Treatment Memory exercises ( If you don t use it, you lose it ) Physical exercise Socialization Memory Exercises Reading Puzzles Educational shows Learning a new language Learning an instrument Brain fit programs? 13

Exercise and cognition Meta analysis Sixteen trials with 937 participants met the inclusion criteria. Authors conclusion: exercise programs can have a significant impact in improving ADLs and cognition No effect on depression or challenging behaviors Metanalysis, Forbes, Thissen, et al, 2014 Exercise and Cognition Can a dementia specific Aquatic exercise program improve behavioral and psychological symptoms in dementia 12 week course and only 10 F and 1 M Improvement was seen in both aspects Neville and Henwood, 2014 14

Exercise and Cognition 30 patient study comparing cognition exercises alone or cognition and physical exercise 12 week study Results showed that the group that participated in both showed improvements in both memory, balance, and quality of life Yoon, Lee 2013 OMT and Dementia Can craniosacral still point technique decrease agitation Cohen Mansfield Agitation Inventory was used to assess agitation CSPT showed a statistical reduction in M CMAI scores Gerder, Hart, and Zimmerman, 2008 15

Music and cognition Cognitive and behavioral effects of music based exercises in patients with dementia. RCT, 15 pts exercise training for three months, which consisted of daily physical exercises supported by music for 30 min/session The present study suggests a beneficial effect of cognition using a music based exercise program in a group of patients with moderate to severe dementia. Winckel and Feys, 2004 Socialization Most social activities involve some type of cognitive process Some activities the caregiver may not have to be present for 16

Case Presentation CDR 1.0 (mild mixed dementia) ChEI Memory and physical exercise Social program Family assistance Follow up visits Monitor progression/confirming diagnosis Medication monitoring Monitor symptoms /adjustments in treatment Caregiver support/education Monitor for potential safety concerns 17

Objectives What are the two most common types of dementias seen in a primary care office How are they staged What treatments are available 18